Table 5.
Characteristics of preferred clinical trials*
| Characteristic | Specialty | Experience | ||
| Gastroenterology (n = 160) | Hepatology (n = 189) | Less Experienced Researchers (n = 159) | More Experienced Researchers (n = 62) | |
| Phase 1 trials | 36 (22.5)† | 73 (38.6)† | 59 (37.1)† | 32 (51.6)† |
| Phase 2 trials | 64 (40.0)† | 107 (56.6)† | 91 (57.2)† | 52 (83.9)† |
| Phase 3 trials | 97 (60.6) | 108 (57.1) | 114 (71.7)† | 53 (85.5)† |
| Phase 4 trials | 76 (47.5)† | 68 (36.0)† | 92 (57.9) | 28 (45.2) |
| Duration ≤ 2 years | 100 (62.5) | 126 (66.7) | 127 (79.9)† | 58 (93.6)† |
| Duration > 2 years | 38 (23.8) | 59 (31.2) | 57 (35.9)† | 35 (56.5)† |
| Trials with placebo or no treatment arm | 51 (31.9) | 55 (29.1) | 68 (42.8) | 28 (45.2) |
| Trials involving invasive procedures | 40 (25.0)† | 30 (15.9)† | 44 (27.7) | 18 (29.0) |
| Multiple-arm and crossover protocols | 36 (22.5) | 35 (18.5) | 40 (25.2)† | 24 (38.7) |
| Industry funding | 76 (47.5) | 104 (55.0) | 86 (54.1)† | 50 (80.7)† |
| Government funding | 78 (48.8)† | 121 (64.0)† | 104 (65.4)† | 56 (90.3)† |
| Non-government funding | 78 (48.8) | 103 (54.5) | 96 (60.4)† | 51 (82.3)† |
* Values are expressed as number (percentage) responding "very interested".
† P ≤ .05 for the comparison between specialties or between clinical and non-clinical researchers.